LyseNTech selected for the GloPID-R project

April 01, 2024

  Lysentech (CEO Heejoon Myung) announced that it was selected for the GloPID-R international cooperation project of the Ministry of Science and ICT in 2024. GloPID-R (Global Research Collaboration for Infectious Disease Preparedness) is a global research fund established in 2013 to promote an effective response within 48 hours in the event of a new variant infectious disease with the potential to become a pandemic. Accordingly, the task is to conduct international joint research in the areas of basics/mechanisms, diagnosis, treatment/vaccine development, surveillance/prediction, policy, and quarantine to respond to new variants of infectious diseases.

  LysenTech's counterpart researcher is Professor Jon Iredell of the University of Sydney Medical School in Australia, an authority in the field of infectious diseases who is currently leading Phage Australia, a large-scale bacteriophage clinical trial. Phage Australia is a clinical project launched in 2022 with the support of the Australian government, with more than 17 clinical centers in Australia participating and has successfully performed more than 30 bacteriophage clinical treatments to date.

  Through this project, Lysentech will develop an engineered phage loaded with patented endolysin and promote its application in Phage Australia.

  Minsoo Kim, head of Lysentech's research center, explained, “We will accelerate the development of bacteriophages as new antibiotics by solving the problem of securing patents for therapeutic phages, which has been one of the biggest challenges in the development of bacteriophage treatments.”